china


Cliff Reid on Regulation and Genomic Medicine

Guest:

Cliff Reid, CEO, Complete Genomics

Bio and Contact Info

Listen (3:55) What do you make of recent crackdown on genetic testing in China?

Listen (5:19) Self pay model better for health care

Listen (2:08) What is the right level of regulation?

Listen (5:22) A two-tiered approach to delivering genomic information

Listen (2:00) How has your focus changed since the buyout?

Listen (3:48) FDA regulation not the only way to raise quality of genomic testing

Listen (2:11) What's your reaction to Illumina announcement of $1,000 genome?

Listen (4:13) What is the cost for genome interpretation today?

In a recent blog, 5 Myths of Genomic Medicine, we quoted Cliff Reid, CEO of Complete Genomics, as saying that the mainstream adoption of genomic medicine might well happen first in a country outside the U.S. and very likely in China where there is more appetite for risk.

Well, a month ago or so, many of us were surprised to read that China is cracking down on genetic testing. So for our first show in a new series, Regulation and Genomic Medicine, we invited Cliff to come back on the program and tell us what he knows about the recent regulatory actions in China and how Complete's parent company, BGI, is responding.

What is the right level of regulation back here in the U.S.? And what is Cliff's reaction to the recent letter sent by the FDA to 23andMe stopping the sale of health related genomic information?

In his answers, Cliff hints at a possible two-tiered system for delivering genomic data: one avenue through the clinics that is regulated by the FDA, the other directly to consumers in a 'interpret the data on your own' kind of way.

What's are his thoughts on Illumina's claim to the $1,000 genome, and how costly is human genome interpretation today? Cliff is forthright, provocative, and prescient.

Podcast brought to you by: Myraqa Clinical Research: The CRO for Point of Care and PMA Diagnostics.

Pharma in China Being Held to Higher Standard, Says Greg Scott, ChinaBio

Guests:

Greg Scott, Founder, ChinaBio

Bio and Contact Info

Listen (5:03) Growth continuum in China unchanged

Listen (4:29) Why has China gone from 1st to 9th for outsourcing?

Listen (6:04) Perstective on GSK scandal

Listen (2:38) If you're not in China, you're missing out on soon to be second largest pharma market

Listen (3:57) Are you seeing innovation in China?

Listen (2:35) Living in China

Greg Scott is Mr. Bio in China. He's the CEO of ChinaBio, a sort of Burrill and Company located in Shanghai.

We caught up with Greg to see what's been happening in China this last year and to get his perspective on the recent GSK scandal. According to Greg, China is still the high growth story that it's been over the past few years. His message to others: If you're not in China you're missing out on what will soon be (next year?) the second largest pharma market in the world.

And what about the GSK scandal? Is it threatening pharma in China? Greg says the importance of the scandal cannot be underestimated. He argues that pharma's enterprises in China are being held to a higher standard, even than in the U.S. or Europe for various reasons. Greg is open about the issues and bullish on opportunity for bio in China.

After Buyout, Cliff Reid, Complete Genomics Stay on Track

Podcast brought to you by: Ingenuity Variant Analysis - Identify causal variants from human sequencing data in just hours.

Guests:

Cliff Reid, PhD, CEO, Complete Genomics Bio and Contact Info

Listen (3:32) Audience questions about Long Fragment Read technology

Listen (3:53) From 200 to 5000 people

Listen (4:11) How do you respond to national security questions?

Listen (4:39) Genomic tests will be commodotized like computers

Listen (7:38) Thoughts on bioinformatics

Listen (2:44) Conversation of bioethics being changed by Facebook generation

Listen (2:51) Future role at the company

In March of 2006, Cliff Reid teamed up with Rade Drmanac and John Curson and founded a company to commercialize a new DNA sequencing platform. But rather than make another sequencing tool and sell it, the company, known as Complete Genomics, would use a different model. They would be devoted entirely to sequencing human genomes as a service. In February of 2009 the company announced its first human genome. By the end of '09, Complete had sequenced 50 human genomes. And in the 3rd quarter of 2010, they sequenced and analyzed 300 human genomes. In 2012, BGI, or Beijing Genomics Institute, offered to purchase Complete for $117 million, and after clearing regulatory hurdles in the US and China, on March 18th the acquisition of Complete was complete.

CEO, Cliff Reid, joins us today in one of his first interviews after the buyout sounding as enthusiastic and on track as he did in our earlier interview. He admits there's a joke in his family that "the fourth time is the charm," because he was involved with two other startups that were ahead of their time. Cliff will be staying on as CEO with the same vision of advancing clinical genome sequencing. He says the company will be commercializing their LFR or Long Fragment Read technology, and he answers questions from our audience about when and how. Acknowledging that the company didn't have the staying power to get to the clinical market and were squeezed out of the research market by an unforeseen preference for exome sequencing, Cliff is still bullish that the price of genome tests must continue to come down further to make a difference in healthcare around the world.

Best of mendelspod - Highlights 2011

Podcast Sponsor: Ingenuity- iReport: The fastest way to get meaning from your expression data

Listen (3:50) Steve Burill: New Model for Big Pharma

Listen (7:06) Dan Vorhaus: The Myriad Case

Listen (3:36) Russ Altman: Personal Genomics and Patent Law

Listen (3:43) Mike Snyder: Million Dollar Interpretation

Listen (2:50) Howard McLeod: PGENI

Listen (2:08) Jonathan Eisen: Why Open Science?

Listen (3:12) George Church: Scientists and the Public

Listen (4:25) Ron Davis: Fit Between University and Industry

Listen (3:01) Greg Scott-Will China Soon Have a Steve Jobs?

As we approach the last day of 2011, we thought we’d look back and bring you highlights of the year, the very best of mendelspod. Included in today’s show are snippets from industry leaders on personalized medicine, the evolution of big pharma, gene patents, and thoughts on open science.

NOTE: It’s important to acknowledge that mendelspod has been made possible through the generous support of our sponsors throughout the year. We thank all of them for their partnership. We wish them and all of you a very happy holiday.

China Fast Becoming No. 1 Market for Pharma with Greg Scott

This podcast was originally aired on October 27th, 2011

Sponsored by: BioConference Live

Guest:

Greg Scott, Founder and President of ChinaBio(R) LLC, Bio and Contact Info

About ChinaBio Listen (9:53) About ChinaBio

Executive retreat 1st of its kind Listen (10:00) Executive retreat 1st of its kind

China becoming no.1 market for pharma Listen (4:11) China becoming no.1 market for pharma

Innovation Listen (9:25) Innovation

Will China soon have a Steve Jobs Listen (6:20) Will China soon have a Steve Jobs?

What is the opportunity for American businesses Listen (3:34) What is the opportunity for American businesses?

Life in China for the American Listen (7:46) Life in China for the American

China doesn't need our help, we need their help Listen (1:42) China doesn't need our help, we need theirs

In 2007, biotech angel investor Greg Scott started ChinaBio to connect China’s life science community with the world, which has helped large, multinational companies such as Pfizer, Roche and Life Technologies, and smaller domestic Chinese companies achieve success in China. ChinaBio has organized 20 conferences, and has generated $400M in funding.   Greg puts out a widely read newsletter on China’s life science industry, ChinaBio® Today. 



New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup